MINNEAPOLIS, June 15 Orasi MedicalŪ today announced that it has entered an agreement with H. Lundbeck A/S (Lundbeck) to study the effect of Lundbeck central nervous system (CNS) compounds on the human brain.
With the average time to bring a CNS drug to market exceeding 12 years - and only 7 percent of neurological drugs making it to market, pharmaceutical companies are looking for technologies to assess the effect of drugs earlier and more accurately in the drug development process. Orasi Medical's technology can accelerate drug development, reduce costs and improve CNS drug innovation by accurately measuring neurological drug effects and real-time brain function throughout key phases of the drug development process. Under the agreement, Lundbeck will utilize Orasi Index(TM) to ascertain the effects of one of its CNS compounds, and compare drug effects to the largest commercial database of magnetoencephalography (MEG) brain scans and supporting clinical data for CNS drugs and CNS disorders.
"By identifying the right drug and dose early, we will help companies like Lundbeck develop more effective drugs for the many people that are affected by CNS diseases," said Sarah Haecker, Vice President of Pharmaceutical Business Development. "Our novel biomarker technology, Orasi Index, can objectively measure if the drug is reaching the brain and what effect the drug is having. It is a huge leap forward for pharmaceutical drug development processes for a multitude of CNS disorders."
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded by Hans Lundbeck in 1915 in Copenhagen, Denmark, and today employs 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.
About Orasi Medical
Orasi Medical develops products to measure the effect of neurological treatments and track the progression of neurological disorders. Pharmaceutical companies use Orasi Index(TM), the company's flagship product, to reduce costs and improve clinical development of neurological treatments. Orasi's high-resolution measurement of brain function provides a robust, non-invasive and reproducible measure of pharmacodynamics and treatment effect and its software as a service model enables highly efficient web-based analysis and reporting of the results.
For more information, please visit www.orasimedical.com
Contacts: Orasi Medical, Inc Sarah Haecker 763.951.8001, ext. 107
SOURCE Orasi Medical